Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
Today’s news reports address issues such as: Pro-PSA (a pecursor molecule to PSA itself) A review of development-stage markers for prostate cancer detection Understanding the pathology report A Phase I trial of high-dose testosterone in men with metatstatic CRPC
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: atypia, detection, markers, pathology, pro-PSA, risk, testosterone therapy | Leave a Comment »
Today’s news reports deal with: A comparative, single institution study of RALP vs RRP Bone mineral density and osteoporosis in men treated with intermittent hormone therapy Transdermal testosterone therapy in men with castration-resistant prostate cancer In a separate report we have discussed the development of a pre-biopsy risk assessment nomogram that incorporates results from PCA3 [...]
Filed under: Management, Treatment | Tagged: BMD, bone mineral density, intermittent hormone therapy, osterporosis, RALP, retropubic radical prostatectomy, robot-assisted laparoscopic prostatectomy, RRP, testosterone therapy | Leave a Comment »
The historic “prohibition” against the use of testosterone therapy in men with a history of prostate cancer is based on a model that assumes that the androgen sensitivity of prostate cancer extends throughout the range of testosterone concentrations.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: androgen sensitivity, testosterone therapy | 2 Comments »
Search for new and
ongoing trials on the
CTAG PCa web site